Please type a	ptus	sign	(+)	inside	this box	→	v
---------------	------	------	-----	--------	----------	---	---

1

of

4

Sheet

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Attorney Docket Number | ST00001 - US - CNT

Under the Paperwork Reduction Act of 1995, no persons are require	ed to respond to a collection of information	on unless it contains a valid OMB control number.
Substitute for form 1449A/PTO	C	Complete if Known
1115051447101151001 001151	Application Number	Not Yet Assigned
INFORMATION DISCLOSURE	- Filling Date	Filed Concurrently Herewith
STATEMENT BY APPLICANT	First Named Inventor	STUTZMANN
	Group Art Unit	1623
(use as many sheets as necessary)	Examiner Name	L. Maier
		

				U.S. PATENT DOCU	JMENTS		
Examiner Cite	Cite	U.S. Patent		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,	
Initials*	No.1	Number	Kind Code ² (# known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
LM		*5,767,269		HIRSH ET AL	06-16-1998	_	
LM		*6,380,173		STUTZMANN ET AL	04-30-2002		
						_	
					+		
					 		
-							
					+		

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office	Foreign Patent Do Number ⁴	Kind Code ⁵ (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Whare Relevant Passages or Relevant Figures Appear	Те
LM	•	wo	*WO 94/08595		SOBEL	04-28-1994	T HUTES ADDER	1
LM		wo	*WO98/53833		STUTZMANN ET AL	12-03-1998	abs only	
LM		wo	*WO98/53834		MARY ET AL	12-03-1998	alos only	
		-		-				
								+
		├	<u> </u>					+
		1-						\vdash

Signature /Leigh Maier/ Considered 07/06/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box 🛶	7
---	---

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute	for form 1449B/PT	0		Complete if Known				
				Application Number	Not Yet Assigned			
INFO	RMATIOI	ND	ISCLOSURE	Filing Date	Filed Concurrently Herewith			
STAT	FMFNT	BY	APPLICANT	First Named Inventor	STUTZMANN			
0.74.			, LIO,	Group Art Unit	1623			
	(use as many a	sheet	s as necessary)	Examiner Name	L,. Maier			
Sheet	2	of	4	Attomey Docket Number	ST00001 - US - CNT			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
LM		*AGG. TURPIE et al , THE LANCET; 1987; pp. 523-526	
LM		*BATH et al, Low Molecular Weight Heparin in Acute Stroke, EXPERT OPINION INVEST. DRUGS; Vol. 7; No. 8; 1998; pp. 1323-1330	
LM		*DAHL Trond et al, Dalteparin in Acute Ischemic Cerebrovascular Disease: A Safety Study, CEREBROVASCULAR DISEASES; Vol. 7; No. 1; 1997; pp. 23-33	
		*ELIAS of al, LA REVUE DE MEDECINE INTERNE; 1; Vol. XI; 1990; pp. 95-98	
LM		FAREED J et al, Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins, Ann. NY Acad. Sci., Vol. 556, 1989, pp 333-353	
LM		*GORDON David Lee et al., Low Molecular Weight Heparins and Heparinoids and Their Use in Acute or Progressing Ischemic Stroke, CLIN. NEUROPHARMACOL.; Vol. 13; No. 6; 1990; pp. 522-544	
LM		*HARDENBERG et al, Enoxaparin is Superior to Unfractionated Heparin in the Prevention of Thromboembolic Events in Medical Patients at Increased Thromboembolic Risk, BLOOD; Vol. 94; No. 10pt1.suppl.1; Abstract 1767; 1999; pp. 399a	
LM		*HILLBORN M et al, Comparison of the Efficacy of the Low Molecular Weight Heparin Enoxaparin with Ubfractionated Heparin in the Prevention of Deep einThrombosls in Patients with a Cute Ischemic Stroke, BLOOD; Vol. 94; No. 20. Supl, pt1; abstract no.798; Nov. 15,1999; pp. 183a	
LM		*JIANYOU et al, Low-MolWt. Heparin in Treatment of Acute Cerebral Infarction, CHEMICAL ABSTRACTS; Vol. 127; No. 24; Abstract No. 326219z; 1997; pp. 54	
LM		JONAS S et al, Is Low Molecular Weight Heparin a Neuroprotectant, Annal New York Academy of Sciences, Vol. 825, Oct. 1997, pp 389-393	

Examiner Signature	/Leigh Maier/	Date	07/06/2006
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box ->	
**	

PTO/S8/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449B/PT(>	_	Co	emplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	Not Yet Assigned		
		Filing Date	Filed Concurrently Herewith		
		First Named Inventor	STUTZMANN		
0.7			741 1 21074141	Group Art Unit	1623
	(use as many s	heet	s as necessary)	Examiner Name	L. Maier
Sheet	3	of	4	Attorney Docket Number	ST00001 - US - CNT

_		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
LM		*KAY et al, Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke, NEW ENGLAND J. MED.; Vol. 333; No. 24; 1995; pp. 1588-1593	
LM		*KAY et al, Pilto Study of Low Molecular Weight Heparin in the Treatment of Acute Ischemic Stroke, STROKE; Vol. 25; No. 3; 1994-03; pp. 684-685	
LM		*LI Ping-An et al., Posttreatment with Low Molecular Weight Heparin Reduces Brain Edema and Infarct Volume inRats Subjected to Thrombotic Middle Cerebral Artery Occlusion, BRAIN RES.; Vol. 801; No. 1-2; 1998; pp. 220-223	
LM		*PRATT J et al., Enoxaparin reduces cerebral edema after photothrombotic injury in the rat, HAEMOSTASIS, 1998, Vol. 28, pages 78-85	
LM		*PRINS et al, Prophylaxis of Deep Venous Thrombosis with a Low Molecular Weight Heparin (Kabi 2165/Fagmin) in Stroke Patients, HAEMOSTASIS; Vol. 19, No. 5; 1989; pp. 245-250	
LM		*RYU et al, Heparin Reduces Neurological Impairment After Cerebral Air Embolism in the Rabbit, STROKE; Vol. 27; No. 2; 1996; pp. 303-310	
LM		*SAMANA M M et al., Acute Ischemic Stroke and Heparin Treatments, THROMB. HAEMOSTASIS; Vol. 78; No. 1; 1997; pp. 173-179	
LM		*STULLKEN ET AL, The Effects of Heparin on Recovery from Ischemic Brain Injuries in Cats, ANESTH. ANALOG; Vol. 55; No. 5; 1976; pp. 683-687	
		*TAIST INVESTIGATORS, Tinzaparin in Acute IschemieStroke Trial (TAIST), STROKE; Vol. 30; No. 1; 1999-01; pp. 163	1
LM		*YANAKA et al , Reduction of Brian Injury Using Heparin to Inhibit Leukocyte Accumulation in a Rat Model of Transient Focal Cerebral Ischemia. II. Dose-Response Effect and the Therapeutic Window, J. NEUROSURG.; Vol. 85, No. 6; 1996; pp. 1108-1112	

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006
J.g. Line		00113140104	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->
--

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitut	te for form 1449B	PTO		Complete if Known		
				Application Number	Not Yet Assigned	
INFO	DRMATIC	ON DIS	CLOSURE	Filing Date	Filed Concurrently Herewith	
STA	TEMEN1	T BY A	PPLICANT	First Named Inventor	STUTZMANN	
• • • • • • • • • • • • • • • • • • • •			2.0,	Group Art Unit	1623	
(use as many sheets as necessary)				Examiner Name	L. Maier	
Sheet	4	of	4	Attomey Docket Number	ST00001 - US - CNT	

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2				
LM		*ZHENG Jinzhi, Clinical Study on Low-MolWt. Heparin (LLMWH) for Treatment of Acute Cerebral Infarction, CHEMICAL ABSTRACTS; Vol. 130; No. 1; Abstract No. 366b; 1999; pp. 44					
LM		*, Physicians' Desk Reference, 49th Edition, pages 1968-1969, 1995					
		•					

Examiner Signature	/Leigh Maier/	Date 07/06	5/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-98)

a plus sign (+) inside this box
Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known					
Application Number	10/849,356				
Filing Date	05-19-2004				
First Named Inventor	MARY				
Group Art Unit	1623				
Examiner Name	L. Maier				
Attorney Docket Number	ST00001 - US - CNT				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τź
LM		ADACHI et al, Alleviation of ischemic neuronal damage by postischemic loading with histidine in the rat striatum, Brain Res., Vol. 998, Issue 1, Feb., 2004, pp 136-138	
LM		CLARK et al, Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissue, Brain Res., Bull. Vol. 34, Issue 4, 1994, pp 387-392	- -
LM		DIETRICK, Morphological Manifestations of Reperfusion Injury in Brain, Ann. N.Y. Acad. Sci., Vol. 15, Issue 24, June, 1994, pp 15-24	
LM		KOGURE et al, Inflammation of the Brain after Ischemia, Acta Neurochir Suppl (Wien), Vol. 66, 1996, pp 40-43	
LM		McINTOSH et al, Effect of Noncompetitive Blockade of N-Methyl-D-Aspartate Receptors on the Neurochemical Sequelae of Experimental Brain Injury, Journal of Neurochemistry, Vol. 55, Issue 4, 1990, pp 1170-1179	<u></u>
LM		TOULMOND et al, Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window, Brain Res., Vol. 620, 1993,pp 32-41	
LM		ZHANG et al, Aminoguanidine Ameliorates and L-Arginine Worsens Brain Damage From Intraluminal Middle Cerebral Artery Occlusion, Stroke, Vol. 27, No. 2, February, 1996, pp 317-323	
·····			
	1		1

Examiner /Leigh Maier/ Signature	Date Considered	07/06/2006
----------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant Is to place a check mark here if English language Translation is attached.

Please	type	a ptus	sign (+)	inside	this box	→
--------	------	--------	----------	--------	----------	---

Sheet

(use as many sheets as necessary)

of

1

2

Not Yet Assigned

ST00001 - US - CNT

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ons are regulated to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995 Complete if Known Substitute for form 1449A/PTO 10/849,356 **Application Number** INFORMATION DISE Filing Date 05-19-2004 STATEMENT BY First Named Inventor MARY, et. al. GTRADE Group Art Unit 1623

> **Examiner Name Attorney Docket Number**

	U.S. PATENT DOCUMENTS							
Examiner	Cite	U.S. Pater	t Document	Name of Patentee or Applicant	Date of Publication of Pages, Columns, Line			
nitials	No.1	Number	(If Icnown)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
								
_								
			- - 		-			
			- 					
	\dashv		- 					
	t							
					1 1 1			
						 		
					 			
					 			
-	-							
	-				·- 			
						······		
					+	· _ · · · · · · · · · · · · · · · · · ·		

				FORE	IGN PATENT DOCUMENT	rs		
Examiner	Cite	F	oreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6
								<u> </u>
		lacksquare						

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

	PTO/SB/08B ((10-96)
annound for use through	10/31/00	OMB ASS	4-003 4

Please type a plus sign (+) inside this box -> Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE palsons for required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995

Substitute for form 1449B/PTO INFORMATION DISC STATEMENT BY (use as many sheets as necessary) 2 2 Sheet of

Complete if Known		
Application Number	10/849,356	
Filing Date	05-19-2004	
First Named Inventor	MARY, et. al.	
Group Art Unit	1623	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	ST00001 - US - CNT)

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initiats Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T2		
LM) -	Tans, L., et. al., Nadroparin Calcium in Treating Ischemic Cerebral Vascular Disease, Chinese Journal of New Drugs and Clinical Remedies, pp. 325-326 Vol.17, No. 6 (1998)	V	
LM		LI, T., et., al., Observations on Sulodexide's Curative effect on Cerebral Vascular Diseases and the Adverse Drug Reaction Thereof, Chinese Journal of New Drugs (1999), Vol.8, No.6, pp.411-412	\checkmark	
-				

i _ / Deidi Maiei/	Date Considered	07/06/2006
--------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.